To the full analysis
Akzo Nobel stock: growth
AKZA.ASAkzo Nobel reported $11.26B in revenue for fiscal 2025, down 5.2% on the prior year, up 3.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−1.6%
per year from 2006 to 2025, per share 0.5%
Earnings (Annual rate)
−3.1%
per year from 2006 to 2025, per share −1%
Free cash flow (Annual rate)
0.4%
per year from 2006 to 2025, per share 2.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 3.6% | −3.7% | −1.6% |
| Revenue per share | 5.9% | −1.3% | 0.5% |
| Earnings | 0.2% | −4.2% | −3.1% |
| Earnings per share | 2.4% | −1.8% | −1.0% |
| Free cash flow | −8.8% | 2.3% | 0.4% |
| Free cash flow per share | −6.7% | 4.9% | 2.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $15.22B | $1.28B | $627.18M |
| 2007 | $11.32B | $10.34B | $798.94M |
| 2008 | $17.08B | −$1.2B | −$490.89M |
| 2009 | $15.39B | $315.81M | $782.32M |
| 2010 | $16.22B | $835.51M | −$16.62M |
| 2011 | $17.39B | $528.56M | −$424.4M |
| 2012 | $17.05B | −$2.4B | −$98.62M |
| 2013 | $16.17B | $802.26M | $55.41M |
| 2014 | $15.84B | $605.02M | $247.11M |
| 2015 | $16.47B | $1.08B | $537.43M |
| 2016 | $15.73B | $1.07B | $734.67M |
| 2017 | $10.65B | $921.94M | $394.48M |
| 2018 | $10.26B | $7.4B | $2.22M |
| 2019 | $10.28B | $597.27M | −$200.57M |
| 2020 | $9.45B | $698.1M | $1.07B |
| 2021 | $10.62B | $918.61M | $351.27M |
| 2022 | $12.02B | $390.05M | −$32.13M |
| 2023 | $11.82B | $489.78M | $924.16M |
| 2024 | $11.87B | $600.59M | $401.13M |
| 2025 | $11.26B | $703.64M | $671.51M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.